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ABSTRACT
Objectives The steroid hormone vitamin D has roles 
in immunomodulation and bone health. Insufficiency is 
associated with susceptibility to respiratory infections. We 
report 25- hydroxy vitamin D (25(OH)D) measurements in 
hospitalised people with COVID- 19 and influenza A and 
in survivors of critical illness to test the hypotheses that 
vitamin D insufficiency scales with illness severity and 
persists in survivors.
Design Cross- sectional study.
Setting and participants Plasma was obtained from 
295 hospitalised people with COVID- 19 (International 
Severe Acute Respiratory and emerging Infections 
Consortium (ISARIC)/WHO Clinical Characterization 
Protocol for Severe Emerging Infections UK study), 93 
with influenza A (Mechanisms of Severe Acute Influenza 
Consortium (MOSAIC) study, during the 2009–2010 H1N1 
pandemic) and 139 survivors of non- selected critical 
illness (prior to the COVID- 19 pandemic). Total 25(OH)D 
was measured by liquid chromatography- tandem mass 
spectrometry. Free 25(OH)D was measured by ELISA in 
COVID- 19 samples.
Outcome measures Receipt of invasive mechanical 
ventilation (IMV) and in- hospital mortality.
Results Vitamin D insufficiency (total 25(OH)D 25–
50 nmol/L) and deficiency (<25 nmol/L) were prevalent in 
COVID- 19 (29.3% and 44.4%, respectively), influenza A 
(47.3% and 37.6%) and critical illness survivors (30.2% 
and 56.8%). In COVID- 19 and influenza A, total 25(OH)
D measured early in illness was lower in patients who 
received IMV (19.6 vs 31.9 nmol/L (p<0.0001) and 22.9 
vs 31.1 nmol/L (p=0.0009), respectively). In COVID- 19, 
biologically active free 25(OH)D correlated with total 
25(OH)D and was lower in patients who received IMV, but 
was not associated with selected circulating inflammatory 
mediators.
Conclusions Vitamin D deficiency/insufficiency was 
present in majority of hospitalised patients with COVID- 19 
or influenza A and correlated with severity and persisted 
in critical illness survivors at concentrations expected to 
disrupt bone metabolism. These findings support early 
supplementation trials to determine if insufficiency is 
causal in progression to severe disease, and investigation 
of longer- term bone health outcomes.
INTRODUCTION
Vitamin D metabolites contribute to bone 
metabolism, calcium homeostasis and 
immunomodulation. Vitamin D is a steroid 
pre-pro- hormone which is converted to the 
main circulating form 25- hydroxy vitamin D 
(25(OH)D), and subsequently to the active 
hormone 1,25 dihydroxy vitamin D. This 
second activation step occurs in the kidney, 
modulated by parathyroid hormone (PTH), 
for ‘endocrine’ calciotropic effects, and also 
under local control within extra- renal tissues, 
including immune cells, for direct action. 
These ‘intracrine’ actions on immune cells 
mediate antimicrobial and anti- inflammatory 
effects.1 The majority of 25(OH)D circulates 
Strengths and limitations of this study
 ► Liquid chromatography- tandem mass spectrometry 
was used to quantify 25- hydroxy vitamin D (25(OH)
D) in plasma samples from well- characterised hos-
pitalised people with COVID- 19 and influenza A and 
survivors of non- selected critical illness.
 ► Biologically active free 25(OH)D was measured by 
ELISA in COVID- 19 plasma samples for the first time.
 ► Samples from people with COVID- 19 and influenza 
A were obtained early in the course of the disease.
 ► Binary logistic regression multivariable models were 
used to assess the association of plasma 25(OH)
D concentration with outcomes in COVID- 19 and 
influenza A, correcting for other known relevant 
covariates.
 ► The observational nature of the study means it is not 
known whether vitamin D status led to poor clinical 
outcome or was a consequence of illness severity.
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bound to proteins, principally vitamin D binding protein 
(85%–90%), and the relatively small unbound (‘free’) 
fraction is available to immune cells.2
In the context of infectious diseases, vitamin D insuffi-
ciency (routinely determined by total 25(OH)D measure-
ment) is associated with increased incidence and severity 
of respiratory tract infections,3–5 including COVID- 19.6 7 
A geographical association between vitamin D deficiency 
prevalence and COVID- 19 incidence and mortality has 
been reported.8 Free 25(OH)D has not yet been investi-
gated in COVID- 19, but this is required to fully understand 
vitamin D status during acute illness and any associations 
with systemic inflammation.9 Clinical trials of vitamin D 
supplementation in respiratory diseases have returned 
mixed results.10–13 Potential beneficial effects of vitamin 
D supplementation may be pathogen- specific and depen-
dent on timing and route of administration. In addition 
to an interest in modifying acute illness outcomes, longer- 
term effects on bone health warrant consideration as crit-
ical illness is associated with loss of bone mineral density 
after recovery.14
In this cross- sectional study, we report measurements 
of total and free 25(OH)D in hospitalised people with 
COVID- 19 and total 25(OH)D in hospitalised people 
with influenza A and survivors of critical illness. We use 
these three data sets to test the hypotheses that vitamin D 
insufficiency in severe respiratory virus infections scales 
with severity and persists in survivors of critical illness.
METHODS
Patients and sampling
COVID-19
The International Severe Acute Respiratory and emerging 
Infections Consortium (ISARIC) WHO Clinical Charac-
terization Protocol for Severe Emerging Infections in the 
UK (CCP- UK) is an ongoing prospective cohort study of 
hospitalised people with COVID- 19, which is recruiting in 
308 hospitals in England, Scotland, Wales and Northern 
Ireland (National Institute for Health Research Clinical 
Research Network Central Portfolio Management System 
ID: 14152), delivered by the ISARIC Coronavirus Clin-
ical Characterisation Consortium (ISARIC4C) investiga-
tors. The protocol, revision history, case report form and 
consent forms are available online at  isaric4c. net. The 
ISARIC/WHO CCP- UK study was registered at https://
www. isrctn. com/ ISRCTN66726260 and designated an 
Urgent Public Health Research Study by the National 
Institute for Health Research UK. A prespecified case 
report form was used to collect data on patient character-
istics, medical interventions received, and outcomes, as 
previously reported.15
Influenza A
Hospitalised patients with influenza A were recruited 
between 2009 and 2010 (the first and second H1N1 
pandemic waves) and 2011 (the first postpandemic 
season) by the Mechanisms of Severe Acute Influenza 
Consortium (MOSAIC) investigators, as previously 
reported.16
Non-selected critical illness survivors
We include a post- hoc analysis of the RECOVER (Eval-
uation of a Rehabilitation Complex Intervention for 
Patients Following Intensive Care Discharge) trial of 
intensive rehabilitation after critical illness.17 Full eligi-
bility criteria have been published previously; briefly, 
adults who had received invasive mechanical ventilation 
(IMV) for at least 48 hours and were considered well 
enough for discharge from the intensive care unit (ICU) 
were recruited. Patients gave additional consent for 
participation in a biomarker substudy and blood samples 
were collected at ICU discharge.18
All participants gave informed consent.
Patient and public involvement
There was no patient or public involvement in this study.
LC-MS/MS methods for total 25(OH)D analysis
EDTA plasma concentrations (on samples obtained on the 
day of enrolment to the study) of 25(OH)D2 and 25(OH)
D3 isoforms were measured by liquid chromatography- 
tandem mass spectrometry (LC- MS/MS) and summed 
to derive the total 25(OH)D concentrations presented 
in the results. For patients with COVID- 19 and critical 
illness survivors, analysis was performed by the Vitamin 
D Animal Laboratory using an assay which has been certi-
fied as proficient by the international Vitamin D External 
Quality Assessment Scheme and described in detail in an 
earlier manuscript, using 200 µL plasma.19 The interassay 
precision (coefficient of variation, CV) of this method 
was <11.5% for both 25(OH)D2 and 25(OH)D3 analytes 
(online supplemental table 1). For patients with influ-
enza A, analysis was performed using another LC- MS/
MS method at a separate clinical biochemistry labora-
tory. The interassay precision of this method was <11% 
for 25(OH)D2 and <10% for 25(OH)D3 (online supple-
mental table 1). Full LC- MS/MS methods are presented 
in online supplemental table 1.
Definition of vitamin D status
In addition to the absolute total 25(OH)D concentra-
tion, the relationship between vitamin D status and 
outcomes is often explored using a total 25(OH)D cut- 
off of 50 nmol/L to define populations that are vitamin 
D sufficient.20 In this study, total 25(OH)D >50 nmol/L 
is reported as ‘sufficient’, 25–50 nmol/L as ‘insufficient’ 
and <25 nmol/L as ‘deficient’ (see online supplemental 
methods).
Free 25(OH)D ELISA
Free 25(OH)D was measured using the Free 25OH Vitamin 
D ELISA (DIAsource ImmunoAssays SA, Belgium), 
following the manufacturer’s instructions, using 10 µL 
of plasma. Absorbance was measured at 450 nm against 
a reference filter set at 630 nm using the Tecan Sunrise 
Microplate Reader (Tecan). GraphPad Prism (V.7.0e for 
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MacOS X) was used to perform a four- parameter logistic 
function to create the calibration curve in order to read 
the mean concentration of duplicate samples. The lower 
limit of detection (LLOD) of the assay was 2.4 pg/mL. 
The intra- assay repeatability (CV) was ≤5.5% across three 
concentrations (low, mid and high concentrations on 
the standard curve) and the interassay precision (CV) 
was <6.5% across the three concentrations, calculated 
based on Clinical and Laboratory Standards Institute 
EP05- A3 and reported in the manufacturer’s guidelines. 
Two control samples (low and high concentrations) were 
analysed in each batch in duplicate and data were only 
reported for the batch if the results of the controls were 
within the acceptance range outlined on each control 
sample vial. Each calibrator, control and patient sample 
were assessed in duplicate and the results only reported if 
the CV of the replicates was <10%.
Statistical analysis
For univariable analyses, the Shapiro- Wilk test was used 
to test for normal data distribution, and then appro-
priate tests, specified in the text, were used for compar-
isons. Associations between covariates and outcomes in 
COVID- 19 and influenza A were assessed with binary 
logistic regression multivariable models. Sex, age, illness 
duration at time of sampling and comorbidity count were 
chosen as covariates. The comorbidity count was derived 
from the same comorbidities (table 1) from the two 
cohorts. To allow for potential non- linear relationship 
between predictors and the probability of an outcome, 
the models included smoothed thin plate regression 
spline terms for age, illness duration at time of sampling, 
comorbidity count and 25(OH)D concentrations. Multi-
variable models were estimated using the gam() function 
Table 1 Characteristics of included patients
Characteristics
COVID- 19
(n=259)
Influenza A
(n=93)
Critical illness survivors
(n=139) P value*
Demographics
  Age at admission, years† 63 (52–73) 43 (29–50) 63 (53–70) <0.0001
  Male sex 175 (67.6) 47 (50.5) 85 (61.2) 0.01
  Day of illness at the time of 
sampling†
10 (6–16) 7 (4–11) 11 (6–18)‡ <0.001§
Comorbidities
  Diabetes mellitus 66 (25.5) 10 (10.8) 23 (16.5) 0.005
  Chronic cardiac disease 57 (22.4) 17 (18.3) 15 (10.8) 0.02
  Obesity, clinician- defined 44 (18.7) 23 (24.7) 28 (20.1) 0.3
  Asthma 41 (16.1) 33 (35.5) 26 (18.7) 0.0002
  Chronic lung disease, not asthma 35 (13.8) 12 (12.9) 24 (17.3) 0.5
  Chronic kidney disease 25 (9.9) 4 (4.3) NA 0.1
  Neoplasia 14 (5.6) 9 (9.7) NA 0.2
  Moderate or severe liver disease 3 (1.2) 4 (4.3) NA 0.08
Illness severity
  Admission to critical care 106 (40.9) 32 (34.4) 139 (100) 0.3§
  Invasive mechanical ventilation 67 (25.9) 29 (31.2) 139 (100) 0.3§
  In- hospital mortality 52 (20.1) 12 (12.9) 4 (2.9)¶ 0.2§
Total plasma 25(OH)D
  Median (IQR), nmol/L 28.5 (17.1–51.9) 28.1 (20.2–37.9) 23.7 (15.3–34.9) 0.01
  Status
  Sufficient (>50 nmol/L) 68 (26.3) 14 (15.1) 18 (12.9) 0.0002
  Insufficient (25–50 nmol/L) 76 (29.3) 44 (47.3) 42 (30.2)
  Deficient (<25 nmol/L) 115 (44.4) 35 (37.6) 79 (56.8)
Data are number (%) unless otherwise stated.
*Kruskal- Wallis, Mann- Whitney or χ2 test as appropriate.
†Median (IQR).
‡Length of ICU stay.
§Comparing COVID- 19 and influenza A.
¶Death after discharge from ICU.
ICU, intensive care unit; NA, not available; 25(OH)D, 25- hydroxy vitamin D.
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of the R mgcv package using the default, thin plate regres-
sion smoothers.21 22 The upper limit of smoother dimen-
sionality was set to 9 for all variables, excluding the 
comorbidity count, where it was set to 7 as this variable 
was discrete with seven levels. Smoother parameters 
were estimated with restricted maximum likelihood. 
25(OH)D concentrations were below the LLOD for 92 
patients (free) and 2 patients (total) in the COVID- 19 
cohort. For the regression models, 25(OH)D values for 
these patients were imputed as the LLOD for the rele-
vant analyte divided by the square root of 2.23 As this is 
a commonly used but arbitrary method the regression 
analysis was repeated using 0 and the LLOD as imputed 
values to assess the sensitivity of the result to this assump-
tion. Effects for categorical covariates are reported as OR; 
smoothed continuous covariates are reported graphically. 
Statistical analyses were conducted in R using the mgcv, 
tidyverse and gratia packages.
RESULTS
Patient characteristics
Samples were obtained from 259 people hospitalised due 
to COVID- 19 and 93 people hospitalised due to influ-
enza A. Samples were also obtained from 139 critical 
illness survivors (prior to the COVID- 19 pandemic) at the 
time of ICU discharge. Patient characteristics, including 
sampling time after symptom onset, are shown in table 1. 
For patients with COVID- 19, samples were obtained 
a median of 3 days (IQR 2–6) after hospital admission. 
Patients with influenza A were younger, more likely to 
be female and more likely to have asthma compared 
with the other cohorts. Receipt of IMV and in- hospital 
mortality did not differ between COVID- 19 and influenza 
A. The WHO Ordinal Severity Scale scores for people 
with COVID- 19 are shown in online supplemental figure 
1, illustrating that the cohort is representative of the 
full spectrum of disease severity in hospitalised people. 
Details on ethnicity were available for the COVID- 19 
and influenza A cohorts. No differences in total 25(OH)
D were observed between ethnic groups, but only small 
numbers of participants were from non- white groups 
(COVID- 19 65 of 259, influenza A 25 of 93; online supple-
mental figure 2). All samples from people with influenza 
A were collected between the months of November and 
February (63.4% in December), whereas all samples from 
people with COVID- 19 were collected between March and 
June (67.6% in April). However, the distribution of total 
25(OH)D measurements did not differ when stratified by 
month (online supplemental figure 3). Total 25(OH)D 
concentration was lower in all three patient cohorts when 
compared with healthy controls (n=36; online supple-
mental figure 4), but the healthy control samples were 
obtained between the months of June and September.
Total 25(OH)D correlates with severity in COVID-19
The majority of patients with COVID- 19 had total 25(OH)
D concentrations indicative of vitamin D insufficiency 
(29.3%) or deficiency (44.4%; table 1). Total 25(OH)D 
was lower in men than in women (median 26.8 (IQR 14.1–
47.4) nmol/L vs median 31.7 (IQR 20.1–63.8) nmol/L, 
p=0.01) and weakly positively correlated with increased 
age (Pearson’s r=0.25, p<0.0001).
When stratified by receipt of IMV as a marker of illness 
severity, total 25(OH)D differed significantly with a 
median concentration of 19.6 nmol/L (IQR 12.6–32.3) in 
patients receiving IMV compared with 31.9 nmol/L (IQR 
20.0–58.3) in the remainder of the cohort (p<0.0001; 
figure 1A). When total 25(OH)D was stratified by asso-
ciated vitamin D status, patients receiving IMV were 
more likely to be insufficient/deficient (figure 1A). 
Among patients who received IMV, 64.2% (43 of 67) were 
deficient and 26.9% (18 of 67) were insufficient. Total 
25(OH)D concentration was also associated with in- hos-
pital mortality (median 23.2 nmol/L (IQR 15.4–39.9) 
in non- survivors vs 29.5 nmol/L (IQR 17.2–55.4) in 
survivors, p=0.01). Total 25(OH)D concentrations were 
divided into quartiles and the proportion of patients 
who received IMV was compared (figure 1B). The lowest 
quartile (≤17.3 nmol/L) had the highest proportion of 
patients receiving IMV (43.1%). The middle quartiles 
were similar (26.6% and 25.0%), with the highest 25(OH)
D quartile (>51.8 nmol/L) containing the lowest propor-
tion receiving IMV (7.8%, χ2 p=0.0001).
Obesity is a risk factor for severity and mortality in 
COVID- 19 and can be associated with vitamin D defi-
ciency.15 However, there was no difference in total 25(OH)
D concentration between patients with/without clinician- 
defined obesity (online supplemental figure 5). Inflam-
matory mediator measurements had previously been 
performed on plasma samples from 66 patients included 
in this study.24 Correlation matrix analysis demonstrated 
that total 25(OH)D was not significantly associated with 
circulating markers of systemic inflammation demon-
strated to be involved in COVID- 19 pathogenesis (online 
supplemental figure 6).
Multivariable analyses confirmed that total 25(OH)
D concentration and vitamin D status (not sufficient) 
were both independently and negatively associated with 
receipt of IMV (table 2, figure 2A and online supple-
mental table 2). Two patients had total 25(OH)D concen-
trations below the LLOD; using 0 and LLOD, instead of 
LLOD divided by the square root of 2, had no substantive 
effect on significance of covariates or their effect sizes. 
Vitamin D status was also independently associated with 
in- hospital mortality, but total 25(OH)D concentration 
was not (online supplemental table 2 and online supple-
mental figure 7A).
Total 25(OH)D correlates with severity in influenza A
We then extended these observations to total 25(OH)
D concentrations measured in people hospitalised with 
influenza A. Total 25(OH)D was not associated with age 
(p=0.1) or sex (p=0.8). Similar to our findings in COVID- 
19, the majority of patients had total 25(OH)D concen-
trations indicative of vitamin D insufficiency (47.3%) or 
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deficiency (37.6%; table 1). When stratified by receipt 
of IMV, total 25(OH)D was lower in patients receiving 
IMV (median 22.9 nmol/L, IQR 18.0–29.8) compared 
with the remainder of the cohort (median 31.1 nmol/L, 
IQR 23.8–45.2, p=0.0009) and these patients were more 
likely to be vitamin D insufficient/deficient (figure 1C). 
Total 25(OH)D was lower in non- survivors compared 
with survivors (median 22.1 nmol/L (IQR 17.6–34.1) 
vs 29.2 nmol/L (IQR 20.6–38.5)), but this was not 
statistically significant (p=0.2). Multivariable analysis 
confirmed an independent negative association between 
total 25(OH)D and receipt of IMV but not in- hospital 
mortality (figure 2B, table 2, online supplemental table 3 
and online supplemental figure 7B).
Vitamin D deficiency persists in survivors of critical illness
In survivors of non- selected critical illness, at the time 
of ICU discharge the median total 25(OH)D concen-
tration was 22.9 nmol/L (IQR 14.6–34.6), similar to 
concentrations in patients with COVID- 19/influenza A 
who required IMV or did not survive. The majority of 
patients had total 25(OH)D concentrations indicative 
of vitamin D deficiency (56.8%) or insufficiency (30.2%; 
figure 1D and table 1). Total 25(OH)D concentration was 
0
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Figure 1 Total 25(OH)D in COVID- 19 and influenza A and in survivors of critical illness. (A) Total 25(OH)D concentrations in 
patients with COVID- 19 (n=295) stratified by receipt of IMV. (B) Total 25(OH)D concentrations from patients with COVID- 19 
were divided into quartiles and the proportion of patients who received IMV in each quartile was compared by χ2 test. (C) 
Total 25(OH)D concentrations in patients with influenza A (from 2009 H1N1 pandemic, n=93) stratified by receipt of IMV. For 
(A) and (C), groups were compared by Mann- Whitney test. The stacked bar charts represent the proportion of patients in each 
subgroup with sufficient (green), insufficient (orange) or deficient (red) total vitamin D status, compared by χ2 test. (D) Total 
25(OH)D concentrations in non- selected critical illness survivors (n=139, recruited prior to the COVID- 19 pandemic) at the time 
of ICU discharge. On violin plots of total 25(OH)D concentrations (nmol/L), the solid line within the plot represents the median 
and the dashed lines represent the IQR. The dotted lines on the y- axis represent the thresholds for total vitamin D insufficiency 
(25–50 nmol/L) and deficiency (<25 nmol/L). 25(OH)D, 25- hydroxy vitamin D; ICU, intensive care unit; IMV, invasive mechanical 
ventilation.
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not associated with age (p=0.7), sex (p=0.7) or length of 
ICU stay (p=0.8). Measurements were not available from 
earlier in these patients’ illnesses.
Free 25(OH)D correlates with severity in COVID-19
In patients with COVID- 19, we found a strong correlation 
between free and total 25(OH)D concentrations (r=0.79, 
p<0.0001) (figure 3A). Free 25(OH)D was lower in 
patients receiving IMV (median 2.4 pg/mL (IQR 2.4–3.4) 
vs 3.6 pg/mL (IQR 2.4–5.7), p<0.0001; figure 3B) but 
was not statistically different between survivors and non- 
survivors on univariable analysis (median 2.8 pg/mL 
(IQR 2.4–4.4) vs 3.3 pg/mL (IQR 2.4–5.3), p=0.2). In 
multivariable analysis, free 25(OH)D was negatively asso-
ciated with both receipt of IMV and in- hospital mortality 
(figure 2B–D and table 2). Free 25(OH)D was not associ-
ated with plasma inflammatory mediator concentrations 
(online supplemental figure 6).
DISCUSSION
Vitamin D insufficiency was prevalent and scaled with 
severity in patients with COVID- 19 and influenza A and 
insufficiency persisted in survivors of critical illness. As 
determined by total 25(OH)D measurement, 73% of 
patients with COVID- 19, 84% of patients with influenza A 
and 87% of critical illness survivors were vitamin D insuf-
ficient/deficient. We demonstrate evidence of a strong 
association between vitamin D status (insufficiency/
deficiency) during illness and both COVID- 19 severity 
(receipt of IMV) and in- hospital mortality, with relevant 
confounders such as sex, age, comorbidities and day of 
illness adjusted for. This observation was replicated in 
influenza A, but the smaller sample size (n=93 compared 
with n=259) limited multivariable analyses. For the first 
time, we demonstrate a similar strong negative association 
between free 25(OH)D and COVID- 19 disease severity 
and mortality. The results from this study extend earlier 
findings from other observational studies reporting asso-
ciations between vitamin D status and SARS- CoV- 2 infec-
tion and COVID- 19 outcome.6 7 25–27
Vitamin D may beneficially modulate the host response 
against SARS- CoV- 2 via intracrine immune signalling. 
Vitamin D enhances intracellular pathogen clearance, 
primarily via the induction of autophagy.28 Importantly, 
the ability of macrophages to produce cathelicidin, which 
has antiviral activity against influenza virus and respira-
tory syncytial virus, correlates with circulating 25(OH)D 
concentrations.29 Although antiviral effects of vitamin D 
have not yet been demonstrated in vitro for SARS- CoV- 2, 
they have been demonstrated for other bacterial and viral 
pathogens.30 31 Consistent with vitamin D having a role in 
local immunomodulation, neither free nor total 25(OH)
D correlated with circulating markers of systemic inflam-
mation involved in COVID- 19 pathogenesis (including 
C- reactive protein, interleukin 6 and granulocyte- 
macrophage colony- stimulating factor24).
Evidence for the importance of free versus total 25(OH)
D in relation to the mechanisms by which vitamin D exerts 
antimicrobial and anti- inflammatory functions has been 
demonstrated.32 33 We now demonstrate that free 25(OH)
D was negatively associated with COVID- 19 severity 
and in- hospital mortality. Studies directly measuring 
free 25(OH)D and immune responses to infection or 
during critical illness are limited. In a study of 30 criti-
cally ill patients, supplementation with high- dose vitamin 
D increased free 25(OH)D and plasma cathelicidin 
concentrations.34 Another study of 30 patients with sepsis 
reported similar results when they examined the effects 
of vitamin D supplementation on bioavailable (combined 
albumin- bound and free fraction) 25(OH)D and catheli-
cidin concentrations.35 Together, these findings suggest 
that low concentrations of free 25(OH)D may reduce 
vitamin D- induced antimicrobial and anti- inflammatory 
response, compromising immune defences.
We found that 30.2% of patients surviving critical illness 
and requiring IMV (prior to the COVID- 19 pandemic) 
were vitamin D insufficient and 56.8% were deficient. 
Table 2 Multivariable analyses of 25(OH)D concentration 
and outcomes
Variable OR P value
Total 25(OH)D
  COVID- 19: receipt of IMV
   Male sex 2.33 (1.13–4.78) 0.022
   Comorbidity count* – 0.487
   Total 25(OH)D* – 0.001
   Day of illness* – 0.386
   Age* – 0.061
  Influenza A: receipt of IMV
   Male sex 2.22 (0.54–9.06) 0.27
   Comorbidity count* – 0.15
   Total 25(OH)D* – 0.016
   Day of illness* – 0.001
   Age* – 0.19
Free 25(OH)D
  COVID- 19: receipt of IMV
   Male sex 2.53 (1.24–5.314) 0.011
   Comorbidity count* – 0.605
   Free 25(OH)D* – 0.006
   Day of illness* – 0.577
   Age* – 0.053
  COVID- 19: in- hospital mortality
   Male sex 2.78 (1.25–6.17) 0.012
   Comorbidity count* – 0.022
   Free 25(OH)D* – 0.025
   Day of illness* – 0.795
   Age* – 0.041
*Smoothed.
IMV, invasive mechanical ventilation; 25(OH)D, 25- hydroxy vitamin 
D.
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Vitamin D deficiency is common in critical illness, with 
a reported prevalence of between 40% and 70% in 
observational studies of both adults and children world-
wide.36 37 Although some patients may enter ICU in a defi-
cient state due to pre- existing disease and malnutrition, 
vitamin D metabolism is dysregulated in critical illness38 
and concentrations fall rapidly after ICU admission.39 
The mechanistic link between acute illness and vitamin D 
deficiency is likely to be multifactorial, including reduced 
dietary intake/absorption, reduced cutaneous synthesis 
due to lack of sunlight and wastage due to reductions 
in vitamin D binding protein.40 Furthermore, vitamin D 
insufficiency/deficiency has been associated with a range 
of poor outcomes in critical illness.37 41–43 Vitamin D insuf-
ficiency leads to secondary hyperparathyroidism and a 
concentration of 50 nmol/L total 25(OH)D is required 
for optimum PTH concentrations.44 Of the critical illness 
survivors, 87% had total 25(OH)D <50 nmol/L, which 
would be associated with secondary hyperparathyroidism 
and the potential for associated loss of bone mineral 
density. Critical illness survivors suffer accelerated loss 
of bone mineral density in the year after ICU discharge 
(compared with matched controls) and increased 10- year 
fracture risk.14 Our findings implicate vitamin D insuffi-
ciency in this process.
There is evidence that vitamin D supplementation can 
improve circulating total 25(OH)D concentrations in 
critically ill patients,34 35 45 but evidence of a beneficial 
effect on outcomes is less clear. High- dose vitamin D 
supplementation in COVID- 1913 and critical illness45 has 
been shown to increase plasma 25(OH)D concentrations 
7 days post supplementation, but no significant reduction 
in the length of hospital stay or acute outcomes, including 
in- hospital mortality, admission to ICU or requirement 
for IMV, was demonstrated.13 45 46 Longer- term outcomes 
such as bone health have not been evaluated. Conversely, 
two randomised trials reported high- dose 25(OH)D3 
(instead of vitamin D3 as in the above- mentioned studies) 
on admission and then subsequent doses on either days 
3 and 7, then weekly (n=76),47 or days 3, 7, 15 and 30 
(n=838),48 were less likely to require ICU admission. We 
identified that vitamin D insufficiency was present early 
in the course of COVID- 19 and influenza A (10 and 7 days 
after symptom onset, respectively), indicating that timing 
of supplementation may be an important factor when 
designing future supplementation studies. We propose 
that future studies examining effects on disease progres-
sion should investigate the effects of vitamin D supplemen-
tation given earlier in the course of the disease, closer to 
symptom onset rather than after hospitalisation. Evidence 
from an observational study of vitamin D supplementation 
usage supports this approach.49 In a cohort of 8297 people 
with SARS- CoV- 2 test results available, habitual vitamin D 
supplement intake prior to the pandemic was associated 
with a reduced risk of a positive test result after correc-
tion for known confounders including demographics 
and comorbidities. Furthermore, despite a decline in 
vitamin D following cardiothoracic surgery, postoperative 
outcomes (including organ dysfunction and mortality) 
are still associated with preoperative vitamin D status.50 
This suggests that supplementation prior to illness onset 
can still be expected to improve outcomes despite the 
fall in vitamin D concentration during acute illness. The 
longer- term effects of persistent vitamin D insufficiency/
deficiency in survivors of critical illness also require 
further investigation especially in the context of bone 
health, which could be independently evaluated using 
sequential measurement of bone turnover markers and 
serum PTH.
The current study has several important limitations. 
The observational design prevents any conclusions about 
a causal role of vitamin D status in poor clinical outcome 
being drawn. We cannot exclude the alternative explana-
tion that the differences in vitamin D status were a conse-
quence of illness severity. Although blood samples were 
obtained from people with COVID- 19 and influenza A as 
soon after hospital admission as feasible, even these early 
measurements will still be subject to acute illness- related 
changes in vitamin D homeostasis. Healthy control data 
are presented (online supplemental figure 4), but these 
samples were obtained between the months of June and 
September, whereas samples from people with COVID- 19 
and influenza A were obtained between November and 
June (although no intermonth variation was observed). 
Data on prehospital or in- hospital vitamin D supplemen-
tation were not available. Finally, longer- term follow- up 
samples to assess vitamin D status in survivors of COVID- 19 
will be informative.
In conclusion, vitamin D deficiency/insufficiency 
was present in the majority of hospitalised patients 
with COVID- 19 or influenza A and scaled with severity, 
highlighting that reduced concentrations of vitamin D 
are common to these disease states and distinct patient 
cohorts. For the first time, free and total 25(OH)D were 
studied in COVID- 19, demonstrating consistent results. 
It is not clear whether vitamin D status led to poor clin-
ical outcome or was a consequence of illness severity. 
Randomised trials will be necessary to determine whether 
a causal relationship exists between vitamin D early in the 
course of the disease and development of critical illness. 
Since vitamin D deficiency/insufficiency persisted at 
concentrations expected to disrupt bone metabolism in 
critical illness survivors, investigation of longer- term bone 
health outcomes is also warranted.
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